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Background: Autoimmune hepatitis (AIH) is a chronic, progressive liver disease,
characterized by continuing hepatocellular inflammation and necrosis. A subgroup of
AIH patients presents specific autoantibodies to soluble liver antigen/liver-pancreas
(SLA/LP) protein, which is regarded as a highly specific diagnostic marker.
Autoantigenic SLA/LP peptides are targeted by CD4+ T cells, and restricted by the
allele HLA-DRB1*03:01, which confers disease susceptibility in Europeans and
Americans. A positively charged residue at position 71 has been indicated as critical
for AIH susceptibility in all of the HLA alleles identified to date. Though the exact
molecular mechanisms underlying pathogenesis of AIH are not clear, molecular
mimicry between SLA/LP and viral/bacterial antigens has been invoked.
Methods: The immunodominant region of SLA/LP was used as query in databank
searches to identify statistically significant similarities with viral/bacterial peptides.
Homology modeling and docking was used to investigate the potential interaction
of HLA-DRB1*03:01 with the identified peptides. By molecular mechanics means, the
interactions and energy of binding at the HLA binding site was also scrutinized.
Results: A statistically significant structural similarity between the immunodominant
regions of SLA/LP and a region of the surface antigen PS 120 from Rickettsia spp. has
been detected. The interaction of the SLA/LP autoepitope and the corresponding
Rickettsia sequence with the allele HLA-DRB1*03:01 has been simulated. The
obtained results predict for both peptides a similar binding mode and affinity to
HLA-DRB1*03:01. A “hot spot” of interaction between HLA-DRB1*03:01 and PS 120 is
located at the P4 binding pocket, and is represented by a salt bridge involving Lys at
position 71 of the HLA protein, and Glu 795 of PS120 peptide.
Conclusions: These findings strongly support the notion that a molecular mimicry
mechanism can trigger AIH onset. CD4+ T cells recognizing peptides of SLA/LP could
indeed cross-react with foreign Rickettsia spp. antigens. Finally, the same analysis
suggests a molecular explanation for the importance of position 71 in conferring the
susceptibility of the allele HLA-DRB1*03:01 to AIH. The lack of a positive charge at
such position could prevent HLA alleles from binding the foreign peptides and
triggering the molecular mimicry event.
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Autoimmune hepatitis (AIH) is a chronic, progressive liver disease, characterized by
continuing hepatocellular inflammation and necrosis. Autoantibodies to several antigens
represent a serological feature of AIH, though most of them are not specific for the disease
[1]. In contrast, autoantibodies to soluble liver antigen and to liver-pancreas (SLA/LP) have
been described as disease specific, suggesting their potential involvement in the pathogen-
esis of AIH, at least in the subgroup of patients presenting SLA/LP autoantibodies (about
20% of AIH cases) [2,3]. Expression, cloning and absorption experiments identified a protein
with homology to a putative UGA suppressor tRNA-associated protein, as the sole target
antigen of SLA/LP autoantibodies [4]. This protein had been previously identified as it co-
precipitated with tRNASec, when mammalian cell extracts were treated with serum from
patients with AIH [5]. Subsequent in vivo and in vitro results therefore identified SLA/LP as
O-phosphoserine (Sep)-tRNA:selenocysteine (Sec)-tRNA synthase (SepSecS, according to
the Nomenclature Commission of the Human Genome Organization). SLA/LP belongs to
the superfamily of pyridoxal 50-phosphate (PLP) dependent enzymes of “fold type I” [6,7],
sharing the same fold and high structural similarity with other members of this group [8,9],
and catalyzing the last step of Sec synthesis, i.e., the conversion of Sep-tRNASec to
Sec-tRNASec [10]. By studying carboxy-terminally truncated SepSecS, Wies et al.
[4] identified an immunodominant region that is specifically recognized by SLA/LP
autoantibodies, and which is located between residues 450–490.
Whereas autoantibodies represent a serological feature of AIH, intrahepatic lymphocytic
infiltrates are the histologic hallmark of AIH, and are regarded as the primary factor for
disease pathogenesis [11]. Indeed, intrahepatic CD4+ T cells recognize self-antigens in the
context of the alleles HLA-DRB1*03:01 and HLA-DRB1*0401, which represent the principal
AIH susceptibility alleles among Europeans and Americans, and in the context of alleles
HLA-DRB1*04:05 and HLA-DRB1*04:04, which are instead linked to AIH susceptibility in
Japan, Argentina and Mexico [12,13]. In particular, a positively charged residue at position
71 in the context of the region 67–72 of the DRβ polypeptide corresponding to the LLEQ
[K/R]R motif, which is shared among the above mentioned HLA alleles, has been indicated
as critical for AIH susceptibility [14]. Recently, HLA-DRB1*03:01 transgenic mice were
immunized with SLA/LP, with the aim of identifying auto-antigenic SLA/LP peptides that
are targeted by CD4+ T cells, and restricted by the disease susceptibility gene HLA-DRB1
*03:01 [15]. Interestingly, the observation that the C-terminal region of SLA/LP spanning
residues 452–465 (sequence NRLDRCLKAVRKER), which was identified as the optimal
CD4+ T cell epitope, overlaps with the SLA/LP sequence that is recognized by antibodies of
patients with AIH suggests that the C-terminal region of SLA/LP is not only targeted by
humoral, but also by cellular immune responses [4,15].
To date, the exact molecular mechanisms that initiate and maintain the production
of autoantibodies in AIH are not clear, though the remarkable uniformity in epitope
recognition shown by SLA/LP autoantibodies suggests a common mechanism [16].
Molecular mimicry between self-antigens and antigens from infectious agents has been
suggested as a mechanism for the generation of autoantibodies [17]. Therefore, it has been
hypothesised that autoimmunity to the SLA/LP protein might be driven by viral/bacterial
antigens, rather than by the SLA/LP antigen itself [16]. Nevertheless, previous attempts to
look for evidence of cross-reactivity of the immunodominant region that is specifically
recognized by SLA/LP autoantibodies with microbial antigens have been unsuccessful [16],
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being driven by molecular mimicry [18].
The present study suggests that local sequence similarity between SLA/LP and a
non-homologous bacterial protein from Rickettsia spp. can drive autoimmunity to
SLA/LP, through initial CD4+ T cell recognition and subsequent humoral response.Methods
Sequence analysis
Residues encompassed by positions 450–495 of SLA/LP autoantigen (O-phosphoserine
(Sep)-tRNA:selenocysteine (Sec)-tRNA synthase) from Homo sapiens [UniProt:Q9HD40,
sequence variant AAD33963.2 according to [4]] were used as query in the non-redundant
(nr) protein sequence database (GenBank CDS translations [19], PDB [20] and UniProtKB/
Swiss-Prot [21]) search, by means of the BLAST server [22]. Algorithm parameters were
kept at their default values except for word size, which was set to 2 to enhance
search sensibility. Sequence display and alignment relied on the program Jalview [23].
Secondary structure and solvent accessibility were predicted with JPred3 [24]. Predictions of
intrinsically disordered regions (IDRs) were carried out as described previously [25].Modeling of the interaction HLA-DRB1*03:01-peptide
The crystal structure of HLA-DRB1*03:01 [UniProt:P01912] in complex with a 15
residues fragment (87–101) of invariant chain called CLIP was obtained by PDB
[PDB:1A6A; [26]]. The CLIP fragment was subsequently used as structural template
to model the potential conformation of other interacting peptides. Molecular modeling
relied on the program Molecular Operating Environment [27] and the PyMod tool [28].
In silico mutagenesis of the side-chains of the CLIP fragment was performed to obtain the
initial complex between HLA-DRB1*03:01 and the target peptide. Then, after manual
adjustment, energy minimization was performed on the whole system. Initially, to allow
added hydrogens to adjust to the crystallographically defined environment, the position of
the heavy atoms of the binary complex were fixed, and steepest descents steps of
energy minimization were performed until the Root Mean Square gradient fell
below the 0.05 Å default threshold. Next, while mainchain atoms were fixed,
sidechains of every residue comprised in a sphere of 20 Å from the docked
peptides were subjected to a gradually decreasing tethering force (from 1000
Kcal·Å-2 to 10 Kcal·Å-2) using again steepest descents, until the Root Mean Square
gradient fell below the default threshold. Finally, a decreasing tethering force
(until the system was totally relaxed) was applied on every atom comprised in a
sphere of 10 Å from the docked peptides, using conjugated gradients, until the
maximum gradient was less than 0.0001 Å. The Amber99 forcefield, a distance-
dependent dielectric constant and a cut-off distance of 40 Å were used during each
simulation.
An approximate estimate of the binding free energy for both complexes was
computed by means of the FastContact 2.0 server [29]. The algorithm implemented
in FastContact is based on a statistically determined desolvation contact potential
and Coulomb electrostatics, and reports residue contact free energies that rapidly
highlight the hotspots of the interaction.
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Boltzmann Solver (APBS) software [30].Results
Sequence similarity and structure analysis
Databank searches identified a set of 120 KDa surface antigens from Rickettsia prowazekii
(for example, PS 120 protein, UniProt:Q9ZD49), sharing a region of high (Score = 29.6
bits; Identities = 16/29 (55%); Positives = 19/29 (66%), Gaps = 0/29 (0%)) and significant
(E-value = 2e−04) similarity with residues 451–479 of SLA/LP (Figure 1). The identified
region of PS 120 protein spans residues 789–817 of Q9ZD49, which are evolutionarily
well conserved amongst other strains and members of the Rickettsiales. In particular, the
sequence segment DDIYNKTQDV at positions 808–817 (Figure 1) is almost invariant
(see Additional file 1). Interestingly, this sequence is also conserved in SLA/LP antigen
where it has been shown to be essential for immune response [16].
The observed sequence similarity between the SLA/LP immunodominant antigen
and the sequence 789–817 of PS 120 kDa protein from R. prowazekii suggests that these
polypeptide regions share a similar secondary structure context. To investigate this issue,
secondary structure, accessibility and IDRs predictions were carried out on the complete
sequences of SLA/LP and PS 120 protein. The results suggest the presence, for the
immunodominant polypeptide region (451–490), of a helix-loop-helix secondary structure
element that is accessible to the solvent. The element (helix-loop-helix) is predicted for
the corresponding polypeptide region of PS 120 protein (Figure 1).
Simulation of the interaction between HLA-DRB1*03:01 and the peptides SLA/LP452-465,
and PS 120790-804.
CD4+ T cells are the main effectors in most autoimmune diseases. Thus, molecular mim-
icry depends on demonstrating that these T cells can be activated by antigenic determinants
of an infectious agent that are similar to the determinants present in the host [31]. A recent
study on auto-antigenic SLA/LP peptides targeted by CD4+ T cells, pinpointed residues
452–465 (hereinafter dubbed peptide “A”, sequence NRLDRCLKAVRKER) of the
C-terminal, immunodominant region of SLA/LP, as the optimal epitope for CD4+ T cells
expressing the AIH disease susceptibility gene HLA-DRB1*03:01 [15]. As shown in Figure 1,Figure 1 Sequence comparison between the autoepitope of SLA/LP and the corresponding region
of the 120 KDa surface antigen from Rickettsia prowazekii. Sequence comparison between the region
encompassing the autoepitope of the human SLA/LP antigen [UniProt:Q9HD40] and the portion of the 120
KDa surface antigen from Rickettsia prowazekii [UniProt:Q9ZD49]. Numbers attached to the accession codes
indicate the sequence positions of the displayed segments within the respective entire sequences. Amino
acid letters are colored according to conservation and physico-chemical properties. Annotations below
alignment indicate the respective predicted secondary structure (red bars represent α-helices) and solvent
accessibility. Sequence positions corresponding to B letters in the lines labeled 25% are predicted to expose
to the solvent less than 25% of their total area. The black bar atop sequences denotes the peptide
interacting with HLA-DRB1*03:01.
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encompassed by positions 790–803 of the PS 120 from Rickettsia prowazekii, (hereinafter
called peptide “B”). However, since it is well known that sequence similarity alone is not
sufficient for mimicry in autoimmune diseases, we decided to model the interaction of
HLA-DRB1*03:01 with peptide “A”, whose interaction has been already proven, and to
compare it with a hypothetical complex between HLA-DRB1*03:01 and peptide “B”
(Figure 2). Residue Leu 454 of peptide “A” (corresponding to Leu 792 of peptide “B”) was
chosen as hydrophobic anchoring sites at the P1 pocket, since: 1) it is well known that filling
this pocket with a hydrophobic residue constitutes a primary requirement for epitope bind-
ing to HLA and epitope selection [32,33]; 2) the P1 pocket of HLA-DRB1*03:01 is located
at the beginning of the peptide binding groove, therefore the hydrophobic anchor site
should be located at the N-terminus or C-terminus of an interacting peptide, and Leu 454
is the only hydrophobic residue of peptide “A” fulfilling this requirement. Following the
choice of the P1 pocket anchoring site, the main-chain of peptide “A” and peptide “B” were
initially modeled by assigning the coordinates of the CLIP fragment. The rationale of this
procedure is that all of the peptides binding to MHC class II adopt a similar type II
polyproline helix conformation, as they interact with the binding groove [34]. In silico
mutagenesis of the side-chains of the CLIP fragment was then performed to obtain initial
HLA-DRB1*03:01-peptide “A” and HLA-DRB1*03:01-peptide “B” complexes. The side-
chain rotamers of peptide “A” and peptide “B” were chosen in order to keep the most simi-
lar orientation of the corresponding CLIP peptide, and to interact with the sameFigure 2 Modeling of the interaction between HLA-DRB1*03:01, SLA/LP452-465, and PS 120790-804.
A) The crystal structure of HLA-DRB1*03:01 is represented as ribbons and transparent surface, with carbon
atoms colored in light grey, oxygen in red, nitrogen in blue and sulfur in yellow. SLA/LP452-465 (peptide “A”)
and PS 120790-804 (peptide “B”) are depicted as cyan and brown sticks, respectively. The location of
anchoring pockets P1, P4, P6 and P9 is also indicated. B) Detail of the P4 binding cleft. This figure was
rendered with PyMOL [35].
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resulting complex.
After manual docking and energy minimization of the complexes, peptide “A” and
“B” showed good predicted binding affinities for HLA-DRB1*03:01 (−33.6 Kcal/mol for
peptide “A” and −28.1 Kcal/mol for peptide “B”). Both peptides twist in the typical type II
polyproline helix, with the sequestration of peptide side chains in polymorphic P1, P4, P6,
and P9 pockets in the HLA protein, which have been identified as major anchors [33].
Table 1 reports the receptor-ligand residue free energy contacts for HLA-DRB1*03:01-pep-
tide “A” and HLA-DRB1*03:01-peptide “B” complexes. As expected, residue Leu 454 of
peptide “A” (Leu 792 of peptide “B”) fits well in the highly hydrophobic P1 pocket, formed
by residues Phe 24, Ile 31, Phe 32, Trp 43, Ala 52, Asn 82, Val 85, Val 86 and Phe 89 of
HLA-DRB1*03:01 (predicted desolvation free energy: −5.624 Kcal/mol and −5.440 for
peptide “A” and “B”, respectively). According to Table 1, a “hot spot” of interaction between
HLA-DRB1*03:01 and peptide “B” is located at the P4 binding pocket, and is represented by
the salt bridges involving Lys at position 71 and Arg at position 74 of the HLA protein, and
Glu 795 of PS120 peptide (Lys 71-Glu 795, −5.191 Kcal/mol; Arg 74-Glu 795, −3.153
Kcal/mol). These interactions are not present in SLA/LP immunodominant peptide,
where the Glu residue is substituted for Cys 457. The P6 binding pocket of HLA-DRB1*
03:01 is negatively charged, being occupied by residues Glu 9 of chain A, Glu 11 and Asp
66 of chain B. In this pocket are accommodated the positively charged residue Lys 459Table 1 Top 10 hot spots of interaction (according to free energy of binding) between
HLA-DRB1*03:01, human SLA/LP452-465, and the corresponding PS 120790-804 from
R. prowazekii
HLA-DRB1*03:01 SLA/LP Free energy (Kcal/mol)
Asp B57 Arg 462 −7.382
Glu A55 Arg 453 −5.015
Asp A66 Lys 459 −4.108
Glu B9 Lys 549 −2.518
Arg A76 Arg 465 −2.381
Leu B53 Arg 462 −2.013
Ser B11 Lys 459 −1.879
Tyr B78 Cys 457 −1.158
Val B85 Leu 454 −1.130
Phe A54 Leu 454 −1.081
HLA-DRB1*03:01 PS 120 Free energy (Kcal/mol)
Lys B71 Glu 795 −5.191
Asp A66 Lys 797 −3.279
Arg B74 Glu 795 −3.153
Glu B9 Lys 797 −2.671
Arg B74 Leu 796 −1.972
Asp B57 Asn 800 −1.425
Tyr B61 Ile 801 −1.235
Glu A55 Arg 794 −1.211
Phe A54 Leu 792 −1.121
Val B85 Leu 792 −1.057
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energy of binding (−3.609 Kcal/mol and −4.072 Kcal/mol, respectively). Finally, the
positively charged side-chain of Arg 462 of peptide “A” is located inside the P9
binding pocket, where it interacts with Asp 57 (chain B) of HLA-DRB1*03:01. The
latter represents the most favourable interaction between HLA-DRB1*03:01 and
peptide “A”, according to residue free energy contacts (−7.382 Kcal/mol). In case
of peptide “B”, Arg 462 is replaced by Asn 800, which is hydrogen-bonded to Asn
69 (chain A) and Asp 57 (chain B) of HLA-DRB1*03:01.Discussion
PLP-enzymes are involved in a number of diseases, including autoimmunity [36-38], and
Bioinformatics approaches have been extensively exploited in the past to understand the
molecular basis of human disorders involving PLP-enzymes [39,40], and to design drugs
specifically targeting such enzymes [41,42].
This study suggests the possible role of molecular mimicry between microbial antigens
and the immunodominant region of a PLP dependent enzyme, SLA/LP. The hypothesis
that foreign antigens of bacterial proteins sharing homology with the SLA/LP protein
might drive autoimmunity, via a molecular mimicry mechanism, has been already debated
[16]. By performing sequence similarity searches in publicly available databases, these
authors identified the protein MJ0610 from the Archaea Methanococcus jannaschii
[GenBank:U67509], a non-pathogenic, hyperthermophillic organism, as the only bacterial
candidate for molecular mimicry to occur. Subsequent attempts to look for evidence of
cross-reactivity of the immunodominant region that is specifically recognized by SLA/LP
autoantibodies with MJ0610 have been unsuccessful [16]. The huge amount of sequence
information that is available nowadays in protein databases prompted us to search again
for bacterial proteins that could be able to trigger an autoimmune response in AIH, on
the base of a molecular mimicry event. The obtained results suggest that a highly signifi-
cant, local sequence similarity between SLA/LP and a non-homologous bacterial protein
from Rickettsia spp. might drive autoimmunity to SLA/LP, through initial CD4+ T cell
recognition and subsequent humoral response.
The PS 120 kDa protein from R. prowazekii is a 1022 residues sequence of unknown
function, belonging to the family of 120 KDa Rickettsia surface antigens [Pfam: 12574]
[43], which may be used as antigens for immune response against the Rickettsia species
[44]. This protein is a close homolog of R. conorii PS 120 kDa protein [UniProt:Q52658;
identities = 640/1019 (63%)], an antigen that is recognized by antirickettsial antibodies in
sera from humans infected with spotted fever group rickettsiae, and that is supposed to
be an important stimulator of the host immune response [44].
Together with mono-dimensional amino acid sequence similarity, the three-dimensional
conformational fit of the immunodominant epitope from host with a polypeptide chain
from the pathogen is also a key aspect in for molecular mimicry to occur [45]. Since
SLA/LP autoantibodies react preferentially with conformational epitopes [46], we
considered the possibility that, beside sequence similarity, the SLA/LP immunodominant
antigen and residues 789–817 of PS 120 kDa protein from Ricketsia spp. could present a
similar secondary structure motif and solvent accessibility. The crystal structure of the
human SepSecS-tRNASec binary complex [PDB: 3HL2] revealed that the first 14 residues
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structure, while the remaining residues (464–501) showed a disordered state and were
not solved in any of the crystal structures of human SepSecS already determined [47-49].
Our structural analysis on the immunodominant region of SLA/LP agrees with previous
bioinformatics studies [50], suggesting that residues 450–490 of SLA/LP fold in a helix-
loop-helix conformation that is accessible to the solvent, and therefore easily recognized
by SLA/LP autoantibodies. Moreover, we suggest that the corresponding region of PS 120
KDa protein could adopt a similar conformation and solvent exposure, which therefore
would render it amenable to the proteolytic cleavage that is necessary for the immune
response to take place.
The recent findings that, of two immunodominant T cell peptides of the SLA/LP protein,
one overlaps with the immunodominant region that is recognized by SLA/LP autoanti-
bodies [15], provide an interesting link between humoral and cell-mediated immune
response in AIH, and prompted us to investigate further this issue, by modeling the inter-
action between the AIH susceptibility allele HLA-DRB1*03:01, human SLA/LP452-465, and
the corresponding PS 120790-802 from R. prowazekii. The obtained complexes predict for
both peptides a similar binding mode and affinity, suggesting that CD4+ T cells recognizing
self-antigens in the context of the alleles HLA-DRB1*03:01 could indeed cross-react with
foreign Rickettsia spp. peptides. Most importantly, a “hot spot” of interaction between
HLA-DRB1*03:01 and peptide “B” is represented by the salt bridges involving Lys at
position 71 and Arg at position 74 of the HLA protein, and Glu 795 of PS120 peptide. This
observation could potentially provide a mechanistic explanation to the fact that a positively
charged residue at position 71 has been indicated as critical for AIH susceptibility in all of
the HLA alleles identified to date [14]. Indeed, the Lys 71-Glu 795 interaction could be
essential for HLA-antigen recognition and binding, and the lack of this interaction could
prevent HLA alleles from binding the foreign peptides and triggering the molecular
mimicry event. Indeed, in the DRB1*1501 allele, which confers resistance to AIH [51], Lys
71 is replaced by an Ala residue. Moreover, beside Lys 71, the presence of Arg at position
74 is also related to an increased susceptibility to AIH [51]. Interestingly, in type 1 diabetes
mellitus, where molecular mimicry has been proposed as an explanation of the pathogenesis
of the disease, a similar mechanism has been observed: an aspartate residue at position 57
of the DQb-β polypeptide chain confers protection, whereas a serine is associated with an
increased risk of disease [52].
Rickettsia is a genus of Gram-negative, obligate intracellular parasites, which are carried
by many ticks, fleas, and lice, and cause diseases in humans such as typhus, rickettsialpox,
Boutonneuse fever, African tick bite fever, Rocky Mountain spotted fever, Flinders Island
spotted fever and Queensland tick typhus (Australian Tick Typhus) [53]. Actually, rickettsial
microorganisms are not necessarily pathogenic species, and are indeed ubiquitous in human
populations, where they normally live in peaceful coexistence with the human beings [54].
These organisms represent one of the closest living relatives to bacteria that originated the
mitochondria inside most eukaryotic cells [55]. Rickettsiales display small, degraded
genomes, with a high propensity of genetic exchange occurring between bacteria that infect
the same host and with the eukaryotic hosts themselves. Crosstalk between host and
bacteria appears to be mediated by proteins containing motifs with high similarity to
eukaryotic-like repeats [53]. The widespread presence of rickettsial microorganisms
amongst humans, the bacteria-host genetic exchange and the local similarity of
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to the emergence of human autoimmune diseases, e.g., multiple sclerosis [54].
Conclusions
Diagnosis of AIH is usually based on a number of outcomes from clinical, laboratory,
and histological exams. Anti-SLA/LP autoantibodies are considered highly specific
markers of AIH [2], and SLA/LP autoantibodies recognize the SLA/LP antigen with
high sensitivity and specificity [4]. On the contrary, commonly detected autoantibodies
such as antinuclear and smooth muscle antibodies are not specific for the disease [3,4].
The presence of different autoantibodies, that is definitively an important part of the final
diagnosis, reflects the complex and diverse interplay between environmental triggering
factors, autoantigens and immunogenetic predisposition of the individual.
Though it is highly unlikely that any single infectious agent would be exclusively
associated with the disease, molecular mimicry provides an elegant framework as to
how cross-reactivity between antigens from a foreign agent with self-proteins may trigger
such disease.
The predicted sequence and structural similarity between the immunodominant epitopes
of the SLA/LP antigen and PS 120 protein from Rickettsia spp. could account for cross-
recognition to occur in autoimmune hepatitis, and contribute to the development of this
disease. The presented findings are supported by coherent and rigorous theoretical consid-
erations and form the basis of a well-grounded hypothesis that can be experimentally tested.
Obviously, CD4+ T cell recognition requires that antigen is degraded by pH-dependent
proteolysis in phago-endosomal compartments of APCs. This means that only a portion of
peptides are efficiently generated from a given antigen and result available to be loaded onto
MHC class II molecules. Several cryptic peptides might not have in vivo relevance, despite
being potential MHC class II binders, if they are not generated during proteolysis of the
entire protein.
To conclude that the suggested peptides are authentic immunodominant T-cell
epitopes, future studies should be aimed at detecting also the frequency of memory B
and T cells specific to PS 120 protein epitope in AIH patients and healthy donors. If
such studies will be confirmed, they may contribute to open new perspectives for AIH
prevention and therapy.
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